The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes

Swapnil N. Rajpathak, Marc J. Gunter, Judith Wylie-Rosett, Gloria Y F Ho, Robert C. Kaplan, Radhika Muzumdar, Thomas E. Rohan, Howard Strickler

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

This review addresses the possible role of the insulin-like growth factor (IGF)-axis in normal glucose homoeostasis and in the etiopathogenesis of type 2 diabetes. IGF-I, a peptide hormone, shares amino acid sequence homology with insulin and has insulin-like activity; most notably, the promotion of glucose uptake by peripheral tissues. Type 2 diabetes as well as pre-diabetic states, including impaired fasting glucose and impaired glucose tolerance, are associated cross-sectionally with altered circulating levels of IGF-I and its binding proteins (IGFBPs). Administration of recombinant human IGF-I has been reported to improve insulin sensitivity in healthy individuals as well as in patients with insulin resistance and type 2 diabetes. Further, IGF-I may have beneficial effects on systemic inflammation, a risk factor for type 2 diabetes, and on pancreatic β-cell mass and function. There is considerable inter-individual heterogeneity in endogenous levels of IGF-I and its binding proteins; however, the relationship between these variations and the risk of developing type 2 diabetes has not been extensively investigated. Large prospective studies are required to evaluate this association.

Original languageEnglish (US)
Pages (from-to)3-12
Number of pages10
JournalDiabetes/Metabolism Research and Reviews
Volume25
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Insulin-Like Growth Factor I
Type 2 Diabetes Mellitus
Carrier Proteins
Homeostasis
Glucose
Insulin Resistance
Insulin
Amino Acid Sequence Homology
Glucose Intolerance
Peptide Hormones
Somatomedins
Fasting
Prospective Studies
Inflammation

Keywords

  • Diabetes
  • Glucose
  • IGFBP
  • Insulin-like growth factor (IGF)-I

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. / Rajpathak, Swapnil N.; Gunter, Marc J.; Wylie-Rosett, Judith; Ho, Gloria Y F; Kaplan, Robert C.; Muzumdar, Radhika; Rohan, Thomas E.; Strickler, Howard.

In: Diabetes/Metabolism Research and Reviews, Vol. 25, No. 1, 2009, p. 3-12.

Research output: Contribution to journalArticle

@article{ac8c9742a88a4dffb29970d8aa0cd9d8,
title = "The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes",
abstract = "This review addresses the possible role of the insulin-like growth factor (IGF)-axis in normal glucose homoeostasis and in the etiopathogenesis of type 2 diabetes. IGF-I, a peptide hormone, shares amino acid sequence homology with insulin and has insulin-like activity; most notably, the promotion of glucose uptake by peripheral tissues. Type 2 diabetes as well as pre-diabetic states, including impaired fasting glucose and impaired glucose tolerance, are associated cross-sectionally with altered circulating levels of IGF-I and its binding proteins (IGFBPs). Administration of recombinant human IGF-I has been reported to improve insulin sensitivity in healthy individuals as well as in patients with insulin resistance and type 2 diabetes. Further, IGF-I may have beneficial effects on systemic inflammation, a risk factor for type 2 diabetes, and on pancreatic β-cell mass and function. There is considerable inter-individual heterogeneity in endogenous levels of IGF-I and its binding proteins; however, the relationship between these variations and the risk of developing type 2 diabetes has not been extensively investigated. Large prospective studies are required to evaluate this association.",
keywords = "Diabetes, Glucose, IGFBP, Insulin-like growth factor (IGF)-I",
author = "Rajpathak, {Swapnil N.} and Gunter, {Marc J.} and Judith Wylie-Rosett and Ho, {Gloria Y F} and Kaplan, {Robert C.} and Radhika Muzumdar and Rohan, {Thomas E.} and Howard Strickler",
year = "2009",
doi = "10.1002/dmrr.919",
language = "English (US)",
volume = "25",
pages = "3--12",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes

AU - Rajpathak, Swapnil N.

AU - Gunter, Marc J.

AU - Wylie-Rosett, Judith

AU - Ho, Gloria Y F

AU - Kaplan, Robert C.

AU - Muzumdar, Radhika

AU - Rohan, Thomas E.

AU - Strickler, Howard

PY - 2009

Y1 - 2009

N2 - This review addresses the possible role of the insulin-like growth factor (IGF)-axis in normal glucose homoeostasis and in the etiopathogenesis of type 2 diabetes. IGF-I, a peptide hormone, shares amino acid sequence homology with insulin and has insulin-like activity; most notably, the promotion of glucose uptake by peripheral tissues. Type 2 diabetes as well as pre-diabetic states, including impaired fasting glucose and impaired glucose tolerance, are associated cross-sectionally with altered circulating levels of IGF-I and its binding proteins (IGFBPs). Administration of recombinant human IGF-I has been reported to improve insulin sensitivity in healthy individuals as well as in patients with insulin resistance and type 2 diabetes. Further, IGF-I may have beneficial effects on systemic inflammation, a risk factor for type 2 diabetes, and on pancreatic β-cell mass and function. There is considerable inter-individual heterogeneity in endogenous levels of IGF-I and its binding proteins; however, the relationship between these variations and the risk of developing type 2 diabetes has not been extensively investigated. Large prospective studies are required to evaluate this association.

AB - This review addresses the possible role of the insulin-like growth factor (IGF)-axis in normal glucose homoeostasis and in the etiopathogenesis of type 2 diabetes. IGF-I, a peptide hormone, shares amino acid sequence homology with insulin and has insulin-like activity; most notably, the promotion of glucose uptake by peripheral tissues. Type 2 diabetes as well as pre-diabetic states, including impaired fasting glucose and impaired glucose tolerance, are associated cross-sectionally with altered circulating levels of IGF-I and its binding proteins (IGFBPs). Administration of recombinant human IGF-I has been reported to improve insulin sensitivity in healthy individuals as well as in patients with insulin resistance and type 2 diabetes. Further, IGF-I may have beneficial effects on systemic inflammation, a risk factor for type 2 diabetes, and on pancreatic β-cell mass and function. There is considerable inter-individual heterogeneity in endogenous levels of IGF-I and its binding proteins; however, the relationship between these variations and the risk of developing type 2 diabetes has not been extensively investigated. Large prospective studies are required to evaluate this association.

KW - Diabetes

KW - Glucose

KW - IGFBP

KW - Insulin-like growth factor (IGF)-I

UR - http://www.scopus.com/inward/record.url?scp=65549095726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549095726&partnerID=8YFLogxK

U2 - 10.1002/dmrr.919

DO - 10.1002/dmrr.919

M3 - Article

VL - 25

SP - 3

EP - 12

JO - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

SN - 1520-7552

IS - 1

ER -